References
- Marshall EC. Racial differences in the presentation of chronic open-angle glaucoma. J Amer Optometric Assoc 1989;60:760–7
- Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412–7
- Palmisano P, Hynes M, Mueller L. Glaucoma and race: a case for screening in Connecticut. Conn Med 2000;64:75–8
- Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. Arch Opthalmol 1991;109:1090–5
- Javitt JC, McBean AM, Nicholson GA, et al. Undertreatment of glaucoma among black Americans. N Engl J Med 1991;325: 1418–22
- AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes I black and white patients within treatment groups. Am J Ophthalmol 2001:132:311–20
- Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122:813–20
- Higginbotham E, Schuman J, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286–93
- Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
- Noecker RJ, Earl ML, Mundorf T, et al. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003;20: 121–8
- Cantor LB, Wudunn D, Cortes A, et al. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49:S12–8
- Cantor LB, Hoop JS, Morgan L. IOP-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006; July 6 [E-pub ahead of print]
- Graham RH, Fusun Cardakli U. Glaucoma, suspect, adult. Available from http://www.emedicine.com/oph/topic127.htm [Last accessed 23 Aug 2006]
- Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20: 149–56
- The AGIS Investigators. The advanced glaucoma intervention study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
- Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120: 1268–79
- Quigley HA, Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83–91
- Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45: S361–8
- Brandt J, VanDenburgh A, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023–31
- Netland PA, Robertson SM, Sullivan EK, et al. Reponse to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20: 149–63
- Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135: 688–703